Catherine Miller

688 total citations
18 papers, 436 citations indexed

About

Catherine Miller is a scholar working on Pathology and Forensic Medicine, Oncology and Epidemiology. According to data from OpenAlex, Catherine Miller has authored 18 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 7 papers in Epidemiology. Recurrent topics in Catherine Miller's work include Multiple Sclerosis Research Studies (16 papers), Polyomavirus and related diseases (6 papers) and Mycobacterium research and diagnosis (6 papers). Catherine Miller is often cited by papers focused on Multiple Sclerosis Research Studies (16 papers), Polyomavirus and related diseases (6 papers) and Mycobacterium research and diagnosis (6 papers). Catherine Miller collaborates with scholars based in United States, Canada and Germany. Catherine Miller's co-authors include Jerome Hanna, Douglas L. Arnold, Ralf Gold, Ludwig Kappos, Robert J. Fox, Amit Bar‐Or, Richard Leigh-Pemberton, Jennifer Lyons, Annette Wundes and Robert T. Naismith and has published in prestigious journals such as Neurology, Multiple Sclerosis Journal and CNS Drugs.

In The Last Decade

Catherine Miller

18 papers receiving 433 citations

Peers

Countries citing papers authored by Catherine Miller

Since Specialization

Citations

This map shows the geographic impact of Catherine Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Miller more than expected).

Fields of papers citing papers by Catherine Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Miller. The network helps show where Catherine Miller may publish in the future.

Co-authorship network of co-authors of Catherine Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Miller. A scholar is included among the top collaborators of Catherine Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Miller. Catherine Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate 2022 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Jennifer Lyons, Richard Hughes, (unknown), (unknown), (unknown), Catherine Miller, Priya Singhal, Karen Smirnakis	7
2	Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics 2022 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Carrie M. Hersh, Arman Altincatal, (unknown), (unknown), Carl de Moor, Richard A. Rudick, James R. Williams, Catherine Miller, Irene Koulinska	7
3	Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies 2022 ·Frontiers in Neurology ·Kunio Nakamura, (unknown), Douglas L. Arnold, Tarek Yousry, Ludwig Kappos, Nancy Richert, (unknown), Catherine Miller, Elizabeth Fisher	3
4	Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence 2021 ·Neurology and Therapy ·(unknown), (unknown), Catherine Miller, (unknown), Jason P. Mendoza, (unknown)	8
5	Effects of Diroximel Fumarate on Brain Volume Change and Disability Progression in Adults With Relapsing-Remitting Multiple Sclerosis From EVOLVE-MS-1 (1262) 2021 ·Neurology ·Jiwon Oh, Douglas L. Arnold, B. Singer, (unknown), Jerome Hanna, Catherine Miller, Robert T. Naismith	1
6	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study 2021 ·Therapeutic Advances in Neurological Disorders ·Annette Wundes, Sibyl Wray, Ralf Gold, B. Singer, Elżbieta Jasińska, Tjalf Ziemssen, J. de Sèze, Pavle Repovic, (unknown), Jerome Hanna, (unknown), Catherine Miller, Robert T. Naismith	16
7	Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results 2021 ·Multiple Sclerosis Journal ·Ralf Gold, Douglas L. Arnold, Amit Bar‐Or, Robert J. Fox, Ludwig Kappos, (unknown), Xiaotong Jiang, Jennifer Lyons, (unknown), Catherine Miller	54
8	Immunomodulatory Effects of DMF Treatment on the Peripheral Lymphocyte Compartment: A Focus on Older MS Patients (478) 2020 ·Neurology ·Fabrizio Giuliani, Erin E. Longbrake, Yang Mao‐Draayer, Derrick Robertson, Amit Bar‐Or, (unknown), (unknown), (unknown), Becky Parks, Chongshu Chen, Catherine Miller	1
9	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study 2020 ·CNS Drugs ·(unknown), Robert T. Naismith, Annette Wundes, Tjalf Ziemssen, Elżbieta Jasińska, Mark S. Freedman, Anthony Lembo, Krzysztof Selmaj, (unknown), (unknown), Jerome Hanna, Richard Leigh-Pemberton, Maria Lopez-Bresnahan, Jennifer Lyons, Catherine Miller, (unknown), Jerry S. Wolinsky	88
10	Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity 2020 ·Multiple Sclerosis Journal ·Erin E. Longbrake, Yang Mao‐Draayer, Mark Cascione, Tomasz Zieliński, (unknown), David Brassat, Chongshu Chen, (unknown), Jason P. Mendoza, Catherine Miller, Becky Parks, (unknown), Derrick Robertson	35
11	Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE 2020 ·Therapeutic Advances in Neurological Disorders ·Ralf Gold, Douglas L. Arnold, Amit Bar‐Or, Robert J. Fox, Ludwig Kappos, Chongshu Chen, Becky Parks, Catherine Miller	41
12	Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes 2019 ·Neurology and Therapy ·(unknown), Stanley Cohan, Enrique Álvarez, Jacob A. Sloane, J. Theodore Phillips, Anneke van der Walt, Irene Koulinska, Fang Fang, Catherine Miller, Andrew Chan	19
13	Real-world Efficacy of Delayed-Release Dimethyl Fumarate in Early Multiple Sclerosis: Interim Results from ESTEEM (P3.2-081) 2019 ·Neurology ·(unknown), Konstantin Balashov, Cynthia C. Jones, Richard Macdonell, Catherine Miller, (unknown), Fan Wu, (unknown)	2
14	Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study 2019 ·Advances in Therapy ·Michael J. Palte, Angela Wehr, (unknown), (unknown), Richard Leigh-Pemberton, Jerome Hanna, Catherine Miller, Natasha Penner	43
15	Effect of dimethyl fumarate on lymphocytes in RRMS 2019 ·Neurology ·Devangi Mehta, Catherine Miller, Douglas L. Arnold, (unknown), Amit Bar‐Or, Ralf Gold, Jerome Hanna, Ludwig Kappos, Shifang Liu, André Palma da Cunha Matta, J. Theodore Phillips, Derrick Robertson, Christian A. von Hehn, Jordana Campbell, Karen Spach, Lili Yang, Robert J. Fox	60
16	Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study 2019 ·Multiple Sclerosis Journal ·Robert T. Naismith, Jerry S. Wolinsky, Annette Wundes, Christopher LaGanke, Douglas L. Arnold, (unknown), Mark S. Freedman, Mark Gudesblatt, Tjalf Ziemssen, Boris Kandinov, (unknown), Maria Lopez-Bresnahan, Narinder Nangia, (unknown), (unknown), (unknown), Shifang Liu, Jerome Hanna, Catherine Miller, Richard Leigh-Pemberton	47
17	Real-world Efficacy of Delayed-Release Dimethyl Fumarate in Early Multiple Sclerosis: Interim Results from ESTEEM 2019 ·(unknown), Konstantin Balashov, Cynthia C. Jones, Richard Macdonell, Catherine Miller, (unknown), Fan Wu, (unknown)	1
18	Quels enjeux sociopolitiques autour de la darija au Maroc 2016 ·HAL (Le Centre pour la Communication Scientifique Directe) ·Dominique Caubet, Catherine Miller	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact